ArticleBMC infectious diseases2025
Extended susceptibility testing for refractory Helicobacter pylori infection: regional testing should guide antimicrobial decision making.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHelicobacter pylori (H. pylori) is a Gram-negative bacterium and common cause of gastritis. Antimicrobial treatment typically involves two agents and is prescribed empirically however therapy can be complicated by drug allergies or previous, unsuccessful regimens. Recent data from Europe suggests rising resistance to commonly used agents but contemporary data relevant to UK populations, particularly following the COVID-19 pandemic is limited. This study aimed to report susceptibility testing results in refractory cases of H. pylori infections to evaluate local resistance patterns, inform treatment strategies, and compare findings with data from the European Registry on H. pylori management.
methodsA retrospective multi-centre cohort study was conducted between September 2018 and September 2023 at North West London Pathology (London, UK), a central laboratory operating through a hub and spoke model, to assess extended antimicrobial susceptibilities in gastric biopsy samples from patients with refractory H. pylori infection. Antimicrobial susceptibilities were assessed using minimum inhibitory concentration methods as per contemporaneous European Committee on Antimicrobial Susceptibility Testing guidelines. Results were compared with European data.
resultsA total of 193 individual isolates were identified. Mean resistance rates were low for tetracycline (2.3%) and amoxicillin (7.3%), moderately low for rifampicin (14.0%), moderate for levofloxacin (27.3%) and high for metronidazole (82.7%) and clarithromycin (75.5%) across the study period. Levofloxacin had a trend of increasing susceptibility (p = 0.10) and rifampicin of increasing resistance (p = 0.31) throughout the study. Resistance rates were significantly higher for the non-naïve North West London cohort compared with the European non-naïve cohort for metronidazole (p < 0.001), amoxicillin (p < 0.01), and clarithromycin (p = 0.02).
conclusionThese findings emphasize the necessity of tailored treatment approaches, informed by regional susceptibility patterns. As antimicrobial resistance continues to evolve a proactive and adaptive approach to treatment strategies remains paramount to effectively treat H. pylori infection and mitigate associated clinical and financial burdens. CLINICAL TRIAL: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.